# Tonix Pharmaceuticals Holding Corp.: financial statements, quarterly

TNXP · Nasdaq · CIK 1430306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tnxp.md) · [Financials](/companies/tnxp/financials.md) · [Filings](/companies/tnxp/filings.md) · [Insiders](/companies/tnxp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tnxp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.0](/filings/0001999371-24-014569.md) | [3.8 d](/filings/0001999371-25-002786.md) | [2.5](/filings/0001999371-25-005875.md) | [2.2](/filings/0001999371-25-011050.md) | [2.8](/filings/0001999371-25-017370.md) | [2.6 d](/filings/0001999371-26-005730.md) | [2.4](/filings/0001999371-26-010486.md) | [2.0](/filings/0001999371-26-017452.md) | [3.3](/filings/0001999371-25-017370.md) | [5.4 d](/filings/0001999371-26-005730.md) | [6.9](/filings/0001999371-26-010486.md) | [13.5](/filings/0001999371-26-017452.md) |
| Cost of revenue | $m | [2.4](/filings/0001999371-24-014569.md) | [2.4 d](/filings/0001999371-25-002786.md) | [1.7](/filings/0001999371-25-005875.md) | [3.4](/filings/0001999371-25-011050.md) | [1.6](/filings/0001999371-25-017370.md) | [1.2 d](/filings/0001999371-26-005730.md) | [0.9](/filings/0001999371-26-010486.md) | [3.3](/filings/0001999371-26-017452.md) | [1.4](/filings/0001999371-25-017370.md) | [1.1 d](/filings/0001999371-26-005730.md) | [1.6](/filings/0001999371-26-010486.md) | [0.7](/filings/0001999371-26-017452.md) |
| Research and development | $m | [21.1](/filings/0001999371-24-014569.md) | [17.1 d](/filings/0001999371-25-002786.md) | [12.9](/filings/0001999371-25-005875.md) | [9.7](/filings/0001999371-25-011050.md) | [9.1](/filings/0001999371-25-017370.md) | [8.3 d](/filings/0001999371-26-005730.md) | [7.4](/filings/0001999371-26-010486.md) | [10.8](/filings/0001999371-26-017452.md) | [9.3](/filings/0001999371-25-017370.md) | [16.9 d](/filings/0001999371-26-005730.md) | [18.2](/filings/0001999371-26-010486.md) | [19.4](/filings/0001999371-26-017452.md) |
| Selling, general and administrative | $m | [8.7](/filings/0001999371-24-014569.md) | [11.6 d](/filings/0001999371-25-002786.md) | [9.3](/filings/0001999371-25-005875.md) | [7.5](/filings/0001999371-25-011050.md) | [7.7](/filings/0001999371-25-017370.md) | [15.6 d](/filings/0001999371-26-005730.md) | [10.1](/filings/0001999371-26-010486.md) | [16.2](/filings/0001999371-26-017452.md) | [25.7](/filings/0001999371-25-017370.md) | [35.7 d](/filings/0001999371-26-005730.md) | [28.6](/filings/0001999371-26-010486.md) | [36.0](/filings/0001999371-26-017452.md) |
| Operating income | $m | [(28.1)](/filings/0001999371-24-014569.md) | [(27.3) d](/filings/0001999371-25-002786.md) | [(21.4)](/filings/0001999371-25-005875.md) | [(77.3)](/filings/0001999371-25-011050.md) | [(15.6)](/filings/0001999371-25-017370.md) | [(22.5) d](/filings/0001999371-26-005730.md) | [(16.1)](/filings/0001999371-26-010486.md) | [(28.3)](/filings/0001999371-26-017452.md) | [(33.1)](/filings/0001999371-25-017370.md) | [(48.3) d](/filings/0001999371-26-005730.md) | [(41.5)](/filings/0001999371-26-010486.md) | [(42.5)](/filings/0001999371-26-017452.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.3](/filings/0001999371-25-017370.md) | [0.3 d](/filings/0001999371-26-005730.md) | not reported | not reported | not reported | [0.0 d](/filings/0001999371-26-005730.md) | not reported | not reported |
| Net income | $m | [(28.0)](/filings/0001999371-24-014569.md) | [(27.3) d](/filings/0001999371-25-002786.md) | [(14.9)](/filings/0001999371-25-017370.md) | [(78.8)](/filings/0001999371-25-017370.md) | [(14.2)](/filings/0001999371-25-017370.md) | [(22.1) d](/filings/0001999371-26-005730.md) | [(16.8)](/filings/0001999371-26-017452.md) | [(28.3)](/filings/0001999371-26-017452.md) | [(32.0)](/filings/0001999371-25-017370.md) | [(46.9) d](/filings/0001999371-26-005730.md) | [(40.2)](/filings/0001999371-26-017452.md) | [(40.6)](/filings/0001999371-26-017452.md) |
| Diluted EPS | $ per share | [(38.63)](/filings/0001999371-24-014569.md) | not reported | [(535.72)](/filings/0001999371-25-005875.md) | [(1920.85)](/filings/0001999371-25-011050.md) | [(22.68)](/filings/0001999371-25-017370.md) | not reported | [(2.84)](/filings/0001999371-26-010486.md) | [(3.86)](/filings/0001999371-26-017452.md) | [(3.59)](/filings/0001999371-25-017370.md) | not reported | [(2.93)](/filings/0001999371-26-010486.md) | [(2.44)](/filings/0001999371-26-017452.md) |
| Basic EPS | $ per share | [(38.63)](/filings/0001999371-24-014569.md) | not reported | [(535.72)](/filings/0001999371-25-005875.md) | [(1920.85)](/filings/0001999371-25-011050.md) | [(22.68)](/filings/0001999371-25-017370.md) | not reported | [(2.84)](/filings/0001999371-26-010486.md) | [(3.86)](/filings/0001999371-26-017452.md) | [(3.59)](/filings/0001999371-25-017370.md) | not reported | [(2.93)](/filings/0001999371-26-010486.md) | [(2.44)](/filings/0001999371-26-017452.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.9](/filings/0001999371-24-014569.md) | [24.9](/filings/0001999371-25-002786.md) | [7.0](/filings/0001999371-25-005875.md) | [4.2](/filings/0001999371-25-011050.md) | [28.2](/filings/0001999371-25-017370.md) | [98.8](/filings/0001999371-26-005730.md) | [132](/filings/0001999371-26-010486.md) | [125](/filings/0001999371-25-011050.md) | [190](/filings/0001999371-25-017370.md) | [208](/filings/0001999371-26-017452.md) | [185](/filings/0001999371-26-010486.md) | [176](/filings/0001999371-26-017452.md) |
| Current assets | $m | [31.3](/filings/0001839882-23-030328.md) | [47.8](/filings/0001999371-25-002786.md) | [30.1](/filings/0001999371-24-005989.md) | [25.3](/filings/0001999371-24-010281.md) | [50.5](/filings/0001999371-24-014569.md) | [119](/filings/0001999371-26-005730.md) | [150](/filings/0001999371-25-005875.md) | [144](/filings/0001999371-25-011050.md) | [208](/filings/0001999371-25-017370.md) | [229](/filings/0001999371-26-017452.md) | [207](/filings/0001999371-26-010486.md) | [203](/filings/0001999371-26-017452.md) |
| Total assets | $m | [139](/filings/0001839882-23-030328.md) | [154](/filings/0001999371-25-002786.md) | [135](/filings/0001999371-24-005989.md) | [70.3](/filings/0001999371-24-010281.md) | [95.0](/filings/0001999371-24-014569.md) | [163](/filings/0001999371-26-005730.md) | [193](/filings/0001999371-25-005875.md) | [187](/filings/0001999371-25-011050.md) | [252](/filings/0001999371-25-017370.md) | [277](/filings/0001999371-26-017452.md) | [258](/filings/0001999371-26-010486.md) | [254](/filings/0001999371-26-017452.md) |
| Current liabilities | $m | [17.7](/filings/0001839882-23-030328.md) | [18.9](/filings/0001999371-25-002786.md) | [20.5](/filings/0001999371-24-005989.md) | [22.0](/filings/0001999371-24-010281.md) | [15.2](/filings/0001999371-24-014569.md) | [18.3](/filings/0001999371-26-005730.md) | [12.1](/filings/0001999371-25-005875.md) | [19.1](/filings/0001999371-25-011050.md) | [21.0](/filings/0001999371-25-017370.md) | [30.8](/filings/0001999371-26-017452.md) | [29.6](/filings/0001999371-26-010486.md) | [30.8](/filings/0001999371-26-017452.md) |
| Total liabilities | $m | [18.4](/filings/0001839882-23-030328.md) | [48.9](/filings/0001999371-25-002786.md) | [27.2](/filings/0001999371-24-005989.md) | [28.2](/filings/0001999371-24-010281.md) | [20.8](/filings/0001999371-24-014569.md) | [23.3](/filings/0001999371-26-005730.md) | [12.5](/filings/0001999371-25-005875.md) | [19.4](/filings/0001999371-25-011050.md) | [21.3](/filings/0001999371-25-017370.md) | [32.0](/filings/0001999371-26-017452.md) | [30.8](/filings/0001999371-26-010486.md) | [31.8](/filings/0001999371-26-017452.md) |
| Long-term debt | $m | not reported | [6.6](/filings/0001999371-25-002786.md) | [6.2](/filings/0001999371-24-005989.md) | [5.7](/filings/0001999371-24-010281.md) | [5.2](/filings/0001999371-24-014569.md) | [4.7](/filings/0001999371-26-005730.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [2.4](/filings/0001999371-25-002786.md) | [2.8](/filings/0001999371-24-005989.md) | [2.8](/filings/0001999371-24-010281.md) | [2.8](/filings/0001999371-24-014569.md) | [2.8](/filings/0001999371-26-005730.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [121](/filings/0001999371-24-014569.md) | [106](/filings/0001999371-26-005730.md) | [108](/filings/0001999371-25-017370.md) | [42.1](/filings/0001999371-25-017370.md) | [74.2](/filings/0001999371-25-017370.md) | [140](/filings/0001999371-26-017452.md) | [180](/filings/0001999371-26-017452.md) | [168](/filings/0001999371-26-017452.md) | [231](/filings/0001999371-25-017370.md) | [245](/filings/0001999371-26-017452.md) | [227](/filings/0001999371-26-017452.md) | [222](/filings/0001999371-26-017452.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.4) d](/filings/0001999371-24-014569.md) | [(22.3) d](/filings/0001999371-25-002786.md) | [(17.6)](/filings/0001999371-25-005875.md) | [(9.9) d](/filings/0001999371-25-011050.md) | [(18.8) d](/filings/0001999371-25-017370.md) | [(14.6) d](/filings/0001999371-26-005730.md) | [(16.6)](/filings/0001999371-26-010486.md) | [(14.8) d](/filings/0001999371-26-017452.md) | [(28.8) d](/filings/0001999371-25-017370.md) | [(39.7) d](/filings/0001999371-26-005730.md) | [(42.3)](/filings/0001999371-26-010486.md) | [(42.2) d](/filings/0001999371-26-017452.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001999371-24-014569.md) | [0.4 d](/filings/0001999371-25-002786.md) | [0.1](/filings/0001999371-25-005875.md) | [0.0 d](/filings/0001999371-25-011050.md) | [0.0 d](/filings/0001999371-25-017370.md) | [0.0 d](/filings/0001999371-26-005730.md) | [0.0](/filings/0001999371-26-010486.md) | [0.5 d](/filings/0001999371-26-017452.md) | [1.0 d](/filings/0001999371-25-017370.md) | [1.9 d](/filings/0001999371-26-005730.md) | [1.7](/filings/0001999371-26-010486.md) | [0.6 d](/filings/0001999371-26-017452.md) |
| Share repurchases | $m | [0.0 d](/filings/0001999371-24-014569.md) | [0.0 d](/filings/0001999371-25-002786.md) | not reported | not reported | not reported | not reported | [3.0](/filings/0001999371-26-010486.md) | [2.9](/filings/0001999371-26-017452.md) | [0.0 d](/filings/0001999371-25-017370.md) | [7.8 d](/filings/0001999371-26-005730.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.8](/filings/0001839882-23-030328.md) | [10.3](/filings/0001999371-24-005989.md) | [0.6](/filings/0001999371-24-010281.md) | [0.7](/filings/0001999371-24-014569.md) | [0.0](/filings/0001999371-25-005875.md) | [0.0](/filings/0001999371-25-011050.md) | [0.6](/filings/0001999371-25-017370.md) | [5.9](/filings/0001999371-26-010486.md) | [7.3](/filings/0001999371-26-017452.md) | [8.9](/filings/0001999371-25-017370.md) | [13.7](/filings/0001999371-26-010486.md) | [16.6](/filings/0001999371-26-017452.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,151,024 at 2026-08-07, from the cover of the [10-Q filed 2026-08-10](/filings/0001999371-26-017452.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.